AR040907A1 - DIBENZOXAZEPINAS, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM - Google Patents
DIBENZOXAZEPINAS, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEMInfo
- Publication number
- AR040907A1 AR040907A1 AR20030103074A ARP030103074A AR040907A1 AR 040907 A1 AR040907 A1 AR 040907A1 AR 20030103074 A AR20030103074 A AR 20030103074A AR P030103074 A ARP030103074 A AR P030103074A AR 040907 A1 AR040907 A1 AR 040907A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituents
- alkylaminocarbonyl
- alkoxycarbonyl
- alkoxy
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Se refiere a compuestos, procedimientos para su preparación, composiciones farmacéuticas que los comprenden así como a su empleo en el tratamiento, composiciones farmacéuticas que los comprenden así como a su empleo en el tratamiento y/o profilaxis de enfermedades en humanos o animales, en especial de enfermedades cardiocirculatorias, por ejemplo la ateroesclerosis. Reivindicacion 1: Compuestos de fórmula 1 en la que Y representa una cadena de alquileno C1-6 que dado el caso contiene uno o más enlaces dobles o triples, en la que, dado el caso, uno o más átomos de carbono est´n sustituidos con oxo y en la que, dado el caso, uno o más átomos de carbono están reemplazados independientemente uno de otro por un átomo de nitrógeno, oxígeno o azufre, donde entre el heteroátomo en Y y R3 se debe encontrar al menos 1 átomo de carbono y donde entre dos heteroátomos en Y se debe encontrar al menos 1 átomo de carbono, R1 representa halógeno, trifluorometilo, trifluorometoxi, ciano, nitro, amino, alquilamino, hidroxi, alquilo, alcoxi, carboxilo, alcoxicarbonilo, aminocarbonilo o alquilaminocarbonilo, donde alcoxicarbonilo y alquilaminocarbonilo pueden estar sustituido con 0, 1 o 2 sustituyentes, donde los sustituyentes se seleccionan independientemente unos de otros a partir del grupo constituido por alcoxi, arilo, hereoarilo, cicloalquilo, heterociclilo y trimetilsililo; n representa 0, 1, 2 o 3 donde con n igual a 2 o 3, los restos R1 pueden ser iguales o diferentes, R2 representa alquilo, donde alquilo puede estar sustituido con 0, 1 o 2 sustituyentes, donde los sustituyentes se seleccionan independientemente unos de ortros del grupo constituido por halógeno, hidroxi, oxo, alcoxi, carboxilo, alcoxicarbonilo, aminocarbonilo, alquilaminocarbonilo, arilo, heteroarilo, cicloalquilo, heterociclilo y heterociclilcarbonilo, donde arilo, heteroarilo, cicloalquilo y heterociclilo pueden estar sustituidos con 0, 1, 2 o 3 sustituyentes, donde los sustituyentes se seleccionan independientmente iunos de otros del grupo constituido por halógeno, trifluorometilo, trifluorometoxi, ciano, nitro, amino, alquilamino, hidroxi, alquilo, alcoxi, carbonilo, alcoxicarbonilo, aminocarbonilo y alquilaminocarbonilo, R3 representa hidroxi o amino, R4 representa halógeno, trifluorometilo, trifluorometoxi, ciano, nitro, amino, alquilamino, hidroxi, alquilo, alcoxi, carboxilo, alcoxicarbonilo, aminocarbonilo, o alquilaminocarbonilo, m representa 0, 1 o 2, donde con m igual a 2 los restos R4 pueden ser iguales o diferentes, o una de sus sales, sus solvatos o los solvatos de sus sales.It refers to compounds, processes for their preparation, pharmaceutical compositions that comprise them as well as their use in the treatment, pharmaceutical compositions that comprise them as well as their use in the treatment and / or prophylaxis of diseases in humans or animals, especially of cardiocirculatory diseases, for example atherosclerosis. Claim 1: Compounds of formula 1 wherein Y represents a C1-6 alkylene chain which, if necessary, contains one or more double or triple bonds, in which, if necessary, one or more carbon atoms are substituted with oxo and in which, if necessary, one or more carbon atoms are independently replaced from each other by a nitrogen, oxygen or sulfur atom, where at least 1 carbon atom must be found between the heteroatom in Y and R3 and where between two heteroatoms in Y must be at least 1 carbon atom, R1 represents halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, alkylamino, hydroxy, alkyl, alkoxy, carboxyl, alkoxycarbonyl, aminocarbonyl or alkylaminocarbonyl, where alkoxycarbonyl and alkylaminocarbonyl may be substituted with 0, 1 or 2 substituents, where the substituents are independently selected from each other from the group consisting of alkoxy, aryl, heloaryl, cycloalkyl, het erocyclyl and trimethylsilyl; n represents 0, 1, 2 or 3 where with n equal to 2 or 3, the R1 moieties may be the same or different, R2 represents alkyl, where alkyl may be substituted with 0, 1 or 2 substituents, where the substituents are independently selected Orthoses of the group consisting of halogen, hydroxy, oxo, alkoxy, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, aryl, heteroaryl, cycloalkyl, heterocyclyl and heterocyclylcarbonyl, where aryl, heteroaryl, cycloalkyl and heterocyclyl can be substituted with 0, 1, or 3 substituents, where the substituents are independently selected from each other from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, alkylamino, hydroxy, alkyl, alkoxy, carbonyl, alkoxycarbonyl, aminocarbonyl and alkylaminocarbonyl, R3 represents hydroxy or amino , R4 represents halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, alkylamino, hydroxy, alkyl, alkoxy, carboxyl, alkoxycarbonyl, aminocarbonyl, or alkylaminocarbonyl, m represents 0, 1 or 2, where with m equal to 2 the R4 moieties may be the same or different, or one of their salts, their solvates or the solvates of their salts.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10242488A DE10242488A1 (en) | 2002-09-13 | 2002-09-13 | New N-alkyl-dibenzoxazepinone derivatives, are aminopeptidase N inhibitors useful for treating cardiovascular, inflammatory, autoimmune or cancer diseases or chronic pain, especially arteriosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040907A1 true AR040907A1 (en) | 2005-04-20 |
Family
ID=31895918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030103074A AR040907A1 (en) | 2002-09-13 | 2003-08-26 | DIBENZOXAZEPINAS, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1539721A1 (en) |
| JP (1) | JP2006503869A (en) |
| KR (1) | KR20050057305A (en) |
| CN (1) | CN1694876A (en) |
| AR (1) | AR040907A1 (en) |
| AU (1) | AU2003266336A1 (en) |
| BR (1) | BR0314109A (en) |
| CA (1) | CA2498658A1 (en) |
| DE (1) | DE10242488A1 (en) |
| GT (1) | GT200300191A (en) |
| MX (1) | MXPA05002702A (en) |
| PL (1) | PL375563A1 (en) |
| TW (1) | TW200413340A (en) |
| UY (1) | UY27973A1 (en) |
| WO (1) | WO2004033437A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004004928A1 (en) * | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
| CA2706903C (en) * | 2007-12-05 | 2015-11-17 | Henricus Jacobus Maria Gijsen | Dibenzoazepine and dibenzooxazepine trpa1 agonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) * | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| JPS58225073A (en) * | 1982-06-25 | 1983-12-27 | Chugai Pharmaceut Co Ltd | Dibenzoxazepinone derivative |
| EP1169042A4 (en) * | 1999-02-17 | 2003-05-02 | Merck & Co Inc | DIBENZO-AZEPINE DERIVATIVES AS ANTAGONISTS OF THE ALPHA V INTEGRIN RECEPTOR |
-
2002
- 2002-09-13 DE DE10242488A patent/DE10242488A1/en not_active Withdrawn
-
2003
- 2003-08-26 AR AR20030103074A patent/AR040907A1/en not_active Application Discontinuation
- 2003-08-30 PL PL03375563A patent/PL375563A1/en not_active Application Discontinuation
- 2003-08-30 MX MXPA05002702A patent/MXPA05002702A/en unknown
- 2003-08-30 KR KR1020057004210A patent/KR20050057305A/en not_active Withdrawn
- 2003-08-30 JP JP2004542338A patent/JP2006503869A/en active Pending
- 2003-08-30 CN CNA038251388A patent/CN1694876A/en active Pending
- 2003-08-30 BR BR0314109-8A patent/BR0314109A/en not_active Application Discontinuation
- 2003-08-30 EP EP03807819A patent/EP1539721A1/en not_active Withdrawn
- 2003-08-30 AU AU2003266336A patent/AU2003266336A1/en not_active Abandoned
- 2003-08-30 WO PCT/EP2003/009666 patent/WO2004033437A1/en not_active Ceased
- 2003-08-30 CA CA002498658A patent/CA2498658A1/en not_active Abandoned
- 2003-09-09 GT GT200300191A patent/GT200300191A/en unknown
- 2003-09-11 UY UY27973A patent/UY27973A1/en not_active Application Discontinuation
- 2003-09-12 TW TW092125127A patent/TW200413340A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004033437A1 (en) | 2004-04-22 |
| GT200300191A (en) | 2004-05-12 |
| UY27973A1 (en) | 2004-04-30 |
| JP2006503869A (en) | 2006-02-02 |
| BR0314109A (en) | 2005-07-26 |
| TW200413340A (en) | 2004-08-01 |
| EP1539721A1 (en) | 2005-06-15 |
| AU2003266336A1 (en) | 2004-05-04 |
| MXPA05002702A (en) | 2005-06-08 |
| DE10242488A1 (en) | 2004-03-25 |
| KR20050057305A (en) | 2005-06-16 |
| PL375563A1 (en) | 2005-11-28 |
| CA2498658A1 (en) | 2004-04-22 |
| CN1694876A (en) | 2005-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE453393T1 (en) | USE OF PYRIDYLAMIDE AS ANGIOGENESIS INHIBITORS | |
| PE20190711A1 (en) | N- (ULFONIL FENILS) BENZAMIDS AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | |
| AR053405A1 (en) | SUBSTITUTED UREA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOPATIAS | |
| ATE478044T1 (en) | BIPHENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS C | |
| CY1112237T1 (en) | 5-Hydroxy-benzothiazole derivative having Beta-2-gonadotropin agonist activity | |
| AR073932A1 (en) | ESTERES COMPOUNDS OF ACID 2- (AMINOMETILIDEN) -4,4-DIFLUORO-3- OXOBUTIRICO AND PROCEDURE FOR PREPARATION | |
| CO6382110A2 (en) | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C. | |
| PE20220948A1 (en) | NEW PIPERIDINIL DERIVATIVES SUBSTITUTED WITH (HETERO) ARYL, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR069512A1 (en) | PIRAZOLOPIRIMIDINAS REPLACED FOR THE TREATMENT OF CNS DISORDERS. PHARMACEUTICAL COMPOSITIONS | |
| PE20081530A1 (en) | NEW COMPOUNDS 617 | |
| NO20060664L (en) | N-substituted benzimidazolyl C-kit inhibitors | |
| NO20090756L (en) | Amino-piperidine derivatives as CETP inhibitors | |
| AR067663A1 (en) | HETEROCICLIC DERIVATIVES OF ETILOXI AMIDAS, COMPOSITIONS THAT INCLUDE THEM AND USES OF THE SAME IN AGRICULTURE OR HORTICULTURE, AS ANTIFUNGIC AGENTS. | |
| DK2203430T3 (en) | N-phenyl-dioxo-hydropyrimidines useful as inhibitors of hepatitis C virus (HCV) | |
| CO6241115A2 (en) | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASAS INHIBITORS | |
| AR082799A1 (en) | DERIVATIVES OF QUINOLINE AND QUINOXALINE AS QUINASE INHIBITORS | |
| GT200600134A (en) | NEW COMPOUNDS OF AMINOSULPHONYL DERIVATIVES | |
| NO20051165L (en) | Benzothiazole derivatives having -adrenoceptor antagonist activity | |
| CO5550450A2 (en) | DERIVATIVES OF 1-ACIL-PIRROLIDINE FOR THE TREATMENT OF VIRAL INFECTIONS | |
| AR049138A1 (en) | USED PIRROLOTRIAZINE DERIVATIVES TO TREAT HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | |
| ECSP10010473A (en) | NEW DERIVATIVES OF CARBAZOL, INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE | |
| UY30050A1 (en) | DERIVATIVES OF PIRIMIDO-OXAZINIL-FENILO, SALTS OF THE SAME, COMPOSITIONS, PREPARATIONS AND APPLICATIONS | |
| AR074623A1 (en) | PROCEDURE FOR THE PREPARATION OF ESTERS OF ACID 2- (AMINOMETILIDEN) -3-OXOBUTIRICO, REPLACED BY HALOGEN | |
| MX2022009059A (en) | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS SELECTIVE AURORA A INHIBITORS. | |
| NO20054340L (en) | New interconnected heterocycles and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |